Valuation: Scholar Rock Holding Corporation

Market Cap 6.63B 5.81B 5.35B 4.97B 9.43B 633B 9.56B 64.06B 24.93B 311B 24.91B 24.37B 1,077B P/E 2026 *
-17.4x
P/E 2027 * -21.7x
Enterprise Value 6.33B 5.55B 5.11B 4.74B 9B 604B 9.12B 61.14B 23.79B 296B 23.78B 23.26B 1,028B EV / Sales 2026 *
972x
EV / Sales 2027 * 42x
Free-Float
99.22%
Yield 2026 *
-
Yield 2027 * -
1 day+1.83%
1 week+2.65%
Current month+2.65%
1 month+28.89%
3 months+13.14%
6 months+27.64%
Current year+28.16%
1 week 51.32
Extreme 51.3195
56.48
1 month 43.23
Extreme 43.23
56.54
Current year 38.75
Extreme 38.75
56.54
1 year 27.07
Extreme 27.07
56.54
3 years 5.93
Extreme 5.93
56.54
5 years 4.32
Extreme 4.325
56.54
10 years 4.32
Extreme 4.325
70
Manager TitleAgeSince
Chief Executive Officer 59 2025-04-26
Director of Finance/CFO 62 2025-04-26
Chief Operating Officer 58 2025-04-26
Director TitleAgeSince
Chairman 59 2017-06-30
Director/Board Member 53 2014-07-31
Director/Board Member 78 2016-09-30
Date Insider Type Main position Quantity % Market Cap.
Jun. 03Free

Director

11,149 0.0097%
Jun. 03Free

Director

11,149 0.0097%
Jun. 03Free

Director

11,149 0.0097%
Change 5-day change 1-year change 3-year change Capi.($)
+1.83%+2.65%+59.12%+700.78% 6.63B
-0.47%-0.32%+73.60%+132.28% 57.73B
-3.80%-6.24%+67.04%+86.36% 54.69B
-0.18%+0.73%-14.83%-12.29% 23.75B
+1.02%+5.97%+16.54%+468.91% 24.18B
-2.70%+4.25%+40.38%-3.72% 19.82B
+3.78%+5.65%+44.99%-26.23% 17.14B
+3.46%+17.72%+206.66%+364.07% 16.75B
-1.81%+18.00%+41.99% - 15.57B
+2.92%+5.16%+29.57%+196.32% 13.96B
Average +0.40%+5.08%+56.51%+211.83% 25.02B
Weighted average by Cap. -0.49%+3.27%+57.77%+154.99%

Financials

2026 *2027 *
Net sales 6.51M 5.7M 5.25M 4.88M 9.26M 621M 9.38M 62.88M 24.47M 305M 24.45M 23.92M 1.06B 149M 131M 121M 112M 213M 14.26B 215M 1.44B 562M 7B 561M 549M 24.26B
Net income -410M -359M -330M -307M -583M -39.08B -590M -3.96B -1.54B -19.18B -1.54B -1.5B -66.51B -356M -312M -287M -267M -507M -33.99B -513M -3.44B -1.34B -16.68B -1.34B -1.31B -57.84B
Net Debt -302M -265M -244M -226M -429M -28.81B -435M -2.92B -1.14B -14.14B -1.13B -1.11B -49.04B -356M -311M -287M -266M -506M -33.92B -512M -3.43B -1.34B -16.65B -1.34B -1.31B -57.72B
Logo Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Employees
289
Date Price Change Volume
26-07-07 $56.27 +1.64% 198,649
26-07-06 $55.36 +0.87% 1,182,409
26-07-02 $54.88 +3.86% 1,726,056
26-07-01 $52.84 -3.93% 1,304,387
26-06-30 $55.00 +0.07% 1,688,113
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
55.36USD
Average target price
59.31USD
Spread / Average Target
+7.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SRRK Stock